Neuroprotective Effects of Sodium Ferulate and Its Antidepressant-Like Effect Measured by Acute and Chronic Experimental Methods in Animal Models of Depression

Yongping Zhang, Lijian Yu, Yanping Wang, Mingneng Liao, Xia Zhang, Rundi Ma, Xiaoyu Zhang, Tingxi Yu

.

DOI: 10.4236/jbbs.2011.12006                

Abstract

Antidepressants with novel targets and without side effects are in great demand. Ferulic acid (FA) is a ubiquitous phenolic acid of low toxicity, and sodium ferulate (SF) is its sodium salt. Our previous studies have revealed that FA and SF show significant protective effect on excitotoxicity, we now test its potential neuroprotective and antidepressant-like effects. MTT assay and morphological analysis by fluorescence microscopy were adopted to measure the neuroprotective effects of SF; forced-swimming, tail-suspension, and chronic mild stress (CMS) tests were performed to assess its antidepressant-like activity. The results showed that SF had protection against H2O2-induced oxidative damage and dexamethasone (DXM)-induced neurotoxicity pheochromocytoma (PC12) cells. Acute administration of SF markedly decreased the duration of immobility during forced-swimming in rats and mice and tail-supension tests in mice. However, SF has no any effects on reserpine-induced hypothermia, 5-hydroxytryptophan-induced head-twitch response, and potentiation of noradrenaline toxicity in mice. Chronic administration of SF reversed the effects of CMS on consumption of food and sucrose solution, weight gain, and histopathology of hippocampus by light microscopy, and potently shortened the immobility time during forced-swimming test following CMS in rats. This study provides evidence that SF possesses obviously antidepressant-like activity, and the antidepressant-like effect may result from its neuroprotective effects.

Keywords

Sodium ferulate, Neuroprotective Effect, PC12 Cells, Animal Models of Depression

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Y. B. Ji, “Pharmacological Action and Application of Blood-Activating and Stasis-Eliminating Available Com-position of Traditional Chinese Medicine,” Heilongjiang Science and Technique Press, Harbin, 1999, pp. 118-121.
[2]	H. Jing, L. Y. Yao, J. S. Li, Y. Q. Song and W. Chao, “Research Progress of Pharmacology of Sodium Ferulate,” Northwest Pharmaceutical Journal, Vol. 17, No. 5, 2002, pp. 236-238.
[3]	E. Grafe, “Anti-oxidant Potential of Ferulic Acid,” Free Radical Biology and Medicine, Vol. 13, No. 4, 1992, pp. 435-448. doi:10.1016/0891-5849(92)90184-I
[4]	B. C. Scott, J. Butler, B. Halliwell and O. I. Aruoma, “Evaluation of the Antioxidant Actions of Ferulic Acid and Catechins,” Free Radical Research Communications, Vol. 19, No. 4, 1993, pp. 241-253. doi:10.3109/10715769309056512
[5]	M. A. Fernandez, M. T. Saenz and M. D. Garcia, “Anti- inflammatory Ac-tivity in Rats and Mice of Phenolic Acids Isolated from Scrophularia Frutescens,” Journal of Pharmacy and Pharmacology, Vol. 50, No. 10, 1998, pp. 1183-1186. doi:10.1111/j.2042-7158.1998.tb03332.x
[6]	Y. Ozaki, “Antiinflammatory Effect of Tetramethylpyra- zine and Ferulic Acid,” Chemical and Pharmaceutical Bulletin, Vol. 40, No. 4, 1992, pp. 954-956.
[7]	A. Suzuki, D. Kagawa, R. Ochiai, I. Tokimitsu and I. Saito, “Green Coffee Bean Extract and Its Metabolites have a Hypoten-sive Effect in Spontaneously Hypertensive Rats,” Hyper-tension Research, Vol. 25, No. 1, 2002, pp. 99-107. doi:10.1291/hypres.25.99
[8]	A. Suzuki, D. Kagawa, A. Fujii, R. Ochiai, I. Tokimitsu and I. Saito, “Short- and Long-Term Effects of Ferulic Acid on Blood Pressure in Spontaneously Hypertensive Rats,” American Journal of Hypertension, Vol. 15, No. 4, 2002, pp. 351-357. doi:10.1016/S0895-7061(01)02337-8
[9]	J. Zhang, Q. Z. Jin and X. G. Wang, “Research Progresses on Synthesis and Pharmacological Activities of Ferulic Acid and Its Derivatives,” Grain and Oil, Vol. 13, No. 1, 2007, pp. 43-45.
[10]	J. J. Yan, J. Y. Cho, H. S. Kim, K. L. Kim, J. S. Jung, S. O. Huh, H. W. Suh, Y. H. Kim and D. K. Song, “Protection against Beta-Amyloid Peptide Toxicity in vivo with Long-Term Administration of Ferulic Acid,” British Journal of Pharmacology, Vol. 133, No. 1, 2001, pp. 89-96.
[11]	Y. P. Zhang, R. D. Ma and L. J. Yu, “Sedative and Hypnotic Effect of Sodium Ferulate in Mice,” Nei Mongol Journal of Traditional Chinese Medicine, Vol. 27, No. 7, 2008, pp. 9-11.
[12]	S. Z. Li, “Compendium of Materia Medica,” (reprinted from 1590 Jinling wood-engraved edition), People’s Health Press, Beijing, 2004, pp. 683-686.
[13]	Jiangsu College of New Medicine, “Dictionary of Traditional Chinese and Herbal Medicine,” Shanghai Science and Technology Publishing House, Shanghai, 1986, pp. 220-222.
[14]	T. X. Yu., Y. Zhao, W. C. Shi, R. D. Ma and L. J. Yu, “Effects of Ma-ternal Oral Administration of Monosodium Glutamate at a Late Stage of Pregnancy on Developing Mouse Fetal Brain,” Brain Research, Vol. 747, No. 2, 1997, pp. 195-206. doi:10.1016/S0006-8993(96)01181-X
[15]	L. J. Yu, Y. P. Zhang, R. D. Ma, L. Bao, J. Z. Fang and T. X. Yu, “Potent Protection of Ferulic Acid against Excitotoxic Effects of Maternal Intragastric Administration of Monosodium Glutamate at a Late Stage of Pregnancy on Developing Mouse Fetal Brain,” European Neuropsy-chopharmacology, Vol. 16, No. 3, 2006, pp. 170-177.
[16]	Y. P. Zhang, L. J. Yu, R. D. Ma, L. Bao, R. Zeng, J. Z. Fang, X. Y. Zhang and T. X. Yu, “Potent Protective Effect of Ferulic Acid on Glutamat-Induced Neurotoxicity in Adult Mice,” Chinese Journal of Neu-romedicine, Vol. 7, No. 6, 2008, pp. 596-599.
[17]	T. J. Shafer and W. D. Atchison, “Methylmercury Blocks N- and L-Type Ca++ Channels in Nerve Growth Fac-tor-Differentiated Pheochromocytoma (PC12) Cells,” Journal of Pharmacology and Experimental Therapeutics, Vol. 258, No. 1, 1991, pp. 149-157.
[18]	M. Yoshizumi, T. Kogame and Y. Suzaki, “Ebselen Attenuates Oxidative Stress-Induced Apoptosis via the Inhibition of the c-Jun N-Terminal Kinase and Activator Protein-1 Signalling Pathway in PC12 Cells,” British Journal of Pharmacology, Vol. 136, No. 2, 2002, pp. 1023-1032. doi:10.1038/sj.bjp.0704808
[19]	M. B. Hansen, S. E. Nielsen and K. Berq, “Re-exami- nation and Further De-velopment of a Precise and Rapid Dye Method for Mea-suring Cell Growth/Cell Kill,” Journal of Immunological Methods, Vol. 119, No. 2, 1989, pp. 203-210. doi:10.1016/0022-1759(89)90397-9
[20]	V. Chigancas, E. N. Miyaji, A. R. Muotri, J. de Fatima Jacysyn, G. P. Amarante-Mendes, A. Yasui and C. F. Menck, “Photore-pair Prevents Ultraviolet-induced Apoptosis in Human Cells Expressing the Marsupial Photolyase Gene,” Cancer Research, Vol. 60, No. 2, 2000, pp. 2458-2463.
[21]	K. Taghzouti, S. Lamarque, M. Kharouby and H. Simon, “Interindividual Differences in Active and Passive Beha-viors in the Forced-Swimming Test: Implications for Animal Models of Psychopathology,” Biological Psychiatry, Vol. 45, No. 6, 1999, pp. 750-758.
[22]	R. D. Porsolt, A. Bertin and M. Jalfre, “Behaviour Despair Models in Mice: A Primary Screening Test for Anti-depressants,” Archives Internationales de Pharmacodyna-mie et de Thérapie, Vol. 229, No. 2, 1977, pp. 327-336.
[23]	R. D. Porsolt, M. Lepichon and M. Jalfre, “Depression: A New Animal Model Sensitive to Antidepressant Treatments,” Nature, Vol. 266, No. 21, 1977, pp. 730-732. doi:10.1038/266730a0
[24]	R. D. Porsolt, G. Anton and N. Blavet, “Behaviour Despair in Rats: A New Model Sensitive to Antidepressant Treatments,” European Journal of Pharmacology, Vol. 47, No. 4, 1978, pp. 379-391. doi:10.1016/0014-2999(78)90118-8
[25]	R. D. Porsolt, “Animal Models of Depression: Utinity for Transgenic Research,” Reviews in the Neurosciences, Vol. 11, No. 1, 2000, pp. 53-58.
[26]	J. M. Vaugeois, G. Passera, F. Zuccaro and J. Costentin, “Individual Differences in Response to Imipramine in the Tail Mouse Suspension Test,” Psychopharmacology, Vol. 134, No. 4, 1997, pp. 387-391.
[27]	P. Willner, A. Towell, D. Sampson, S. Sophokleous and R. Muscat, “Reduction of Sucrose Preference by Chronic Unpredictable Mild Stress, and Its Restoration by a Tricyclic Antidepressant,” Psychophar-macology, Vol. 93, No. 3, 1987, pp. 358-364.
[28]	J. L. Moreau, F. Jenck, J. R. Martin, P. Mortas and W. E. Aefely, “Antidepressant Treatment Prevents Chronic Un-predictabl Mild Stress-Induced Anhedonia as Assessed by Ventral Tegmentum Self-Stimulation Behavior in Rats,” European Neuropsychopharmacology, Vol. 2, No. 1, 1992, pp. 43-49. doi:10.1016/0924-977X(92)90035-7
[29]	K. T. Hallam, J. E. Horgan, C. McGrath and T. R. Norman, “An Inves-tigation of the Effect of Tacrine and Physostigmine on Spatial Working Memory Deficits in the Olfactory Bul-bectomised Rat,” Behavioural Brain Research, Vol. 153, No. 2, 2004, pp. 481-486. doi:10.1016/j.bbr.2004.01.005
[30]	J. J. Zhang, A. Q. Chen, Y. Z. Gao, H. X. Liu and Y. Zhou, “Effect of So-dium Ferulate on Free Intracellular Calcium in Cortical Neuronal Cultures,” Chinese Journal of Clinical Neuros-ciences, Vol. 10, No. 4, 2002, pp. 342-344.
[31]	B. Halliwell and O. I. Aruoma, “DNA Damage by Oxygen-Derived Species. Its Mechanism and Measurement in Mammalian Systems,” FEBS Letters, Vol. 281, No. 1-2, 1991, pp. 9-19. doi:10.1016/0014-5793(91)80347-6
[32]	G. Lucca, C. M. Comim, S. S. Valvassori, G. Z. Réus, F. Vuolo, F. Petronilho, F. Dal-Pizzol, E. C. Gavioli and J. Quevedo, “Effects of Chronic Mild Stress on the Oxidative Para-meters in the Rat Brain,” Neurochemistry International, Vol. 54, No. 5-6, 2009, pp. 358-362. doi:10.1016/j.neuint.2009.01.001
[33]	Y. C. Wei, F. L. Zhou, D. L. He, J. R. Bai, L. Y. Hui, X. Y. Wang and K. J. Nan, “The Level of Oxidative Stress and the Expression of Genes Involved in DNA-Damage Signaling Pathways in Depressive Patients with Colorectal Carcinoma,” Journal of Psychosomatic Research, Vol. 66, No. 3, 2009, pp. 259-266. doi:10.1016/j.jpsychores.2008.09.001
[34]	H. Kato, K. Kogure, T. Araki and Y. Itoyama, “Astroglial and Micro-glial Reactions in the Gerbil Hippocampus with Induced Ischemic Tolerance,” Brain Research, Vol. 664, No. 1994, pp. 69-76.
[35]	N. Kawahara, C. A. Ruetzler, G. Mies and I. Klatzo, “Cortical Spreading Depression Increases Protein Synthesis and Upregulates Basic Fibroblast Growth Factor,” Experimental Neurology, Vol. 158, No. 1, 1999, pp. 27-36.
[36]	PGIS, “Global Terrorism Database 1998-2004. GTD2, Codebook, Draft 1.0,” Pinkerton Global Intelligence Services (PGIS), Washington DC, 2007.
[37]	J. E. Malberg, A. J. Eisch, E. J. Nestler and R. S. Duman, “Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus,” Journal of Neuroscience, Vol. 20, No. 24, 2009, pp. 9104-9110.